These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24113146)

  • 21. Adverse events in medication treatment-naïve children with attention-deficit/hyperactivity disorder: results from a small, controlled trial of lisdexamfetamine dimesylate.
    Wigal SB; Wong AA; Jun A; Stehli A; Steinberg-Epstein R; Lerner MA
    J Child Adolesc Psychopharmacol; 2012 Apr; 22(2):149-56. PubMed ID: 22372513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lisdexamfetamine dimesylate: a prodrug stimulant for the treatment of ADHD in children and adults.
    Mattingly G
    CNS Spectr; 2010 May; 15(5):315-25. PubMed ID: 20448522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A long-term open-label safety and effectiveness trial of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Cutler AJ; Saylor K; Gasior M; Hamdani M; Ferreira-Cornwell MC; Childress AC
    J Child Adolesc Psychopharmacol; 2013 Feb; 23(1):11-21. PubMed ID: 23410138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of lisdexamfetamine dimesylate on parent-rated measures in children aged 6 to 12 years with attention-deficit/hyperactivity disorder: a secondary analysis.
    Lopez FA; Ginsberg LD; Arnold V
    Postgrad Med; 2008 Sep; 120(3):89-102. PubMed ID: 18824828
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lisdexamfetamine dimesylate for childhood ADHD.
    Madaan V
    Drugs Today (Barc); 2008 May; 44(5):319-24. PubMed ID: 18548134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder.
    Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE
    J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A pilot study of stimulant medication for adults with attention-deficit/hyperactivity disorder (ADHD) who are parents of adolescents with ADHD: the acute effects of stimulant medication on observed parent-adolescent interactions.
    Babinski DE; Waxmonsky JG; Waschbusch DA; Humphrey H; Alfonso A; Crum KI; Bernstein M; Slavec J; Augustus JN; Pelham WE
    J Child Adolesc Psychopharmacol; 2014 Dec; 24(10):582-5. PubMed ID: 25386742
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL; Childress AC; Cutler AJ; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lisdexamfetamine: A Review in ADHD in Adults.
    Frampton JE
    CNS Drugs; 2016 Apr; 30(4):343-54. PubMed ID: 27048350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reading performance as a function of treatment with lisdexamfetamine dimesylate in elementary school children diagnosed with ADHD.
    Wigal SB; Maltas S; Crinella F; Stehli A; Steinhoff K; Lakes K; Schuck S
    J Atten Disord; 2012 Jan; 16(1):23-33. PubMed ID: 20978273
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Updated 2018 NICE guideline on pharmacological treatments for people with ADHD: a critical look.
    Faltinsen E; Zwi M; Castells X; Gluud C; Simonsen E; Storebø OJ
    BMJ Evid Based Med; 2019 Jun; 24(3):99-102. PubMed ID: 30530806
    [No Abstract]   [Full Text] [Related]  

  • 33. [Change in the therapeutic strategy when faced with an inadequate response to the pharmacological treatment of attention deficit hyperactivity disorder].
    Gandía-Benetó R; Mulas F; Roca P; Ortiz-Sánchez P; Abad-Mas L
    Rev Neurol; 2015 Feb; 60 Suppl 1():S13-8. PubMed ID: 25726817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM; Earls MF
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.
    Setyawan J; Hodgkins P; Guérin A; Gauthier G; Cloutier M; Wu E; Erder MH
    J Med Econ; 2013 Oct; 16(10):1203-15. PubMed ID: 23937642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design.
    Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L
    J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stimulant drugs for severe hyperactivity in childhood.
    Drug Ther Bull; 2001 Jul; 39(7):52-4. PubMed ID: 11471516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.
    Zimovetz EA; Beard SM; Hodgkins P; Bischof M; Mauskopf JA; Setyawan J
    CNS Drugs; 2016 Oct; 30(10):985-96. PubMed ID: 27530525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders.
    Roncero C; Álvarez FJ
    Expert Rev Neurother; 2014 Aug; 14(8):849-65. PubMed ID: 24948428
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD.
    Dew RE; Kollins SH
    Expert Opin Pharmacother; 2010 Dec; 11(17):2907-13. PubMed ID: 20979573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.